Javier de Castro

2003–2025 年に発表

別表記
Javier De Castro
61
論文数
21,982
被引用数
38
h 指数
56
i10 指数

被引用数

Javier de Castro の年別被引用数1971 年: 被引用 3 件1976 年: 被引用 1 件1993 年: 被引用 1 件1995 年: 被引用 1 件2001 年: 被引用 2 件2003 年: 被引用 1 件2004 年: 被引用 7 件2005 年: 被引用 32 件2006 年: 被引用 22 件2007 年: 被引用 31 件2008 年: 被引用 24 件2009 年: 被引用 21 件2010 年: 被引用 23 件2011 年: 被引用 32 件2012 年: 被引用 61 件2013 年: 被引用 132 件2014 年: 被引用 122 件2015 年: 被引用 161 件2016 年: 被引用 140 件2017 年: 被引用 121 件2018 年: 被引用 223 件2019 年: 被引用 901 件2020 年: 被引用 1,085 件2021 年: 被引用 1,115 件2022 年: 被引用 906 件2023 年: 被引用 735 件2024 年: 被引用 1,141 件2025 年: 被引用 555 件2026 年: 被引用 10 件1972〜1975 年は被引用が無いため表示していません1977〜1992 年は被引用が無いため表示していません1994 年は被引用が無いため表示していません1996〜2000 年は被引用が無いため表示していません2002 年は被引用が無いため表示していません

引用元

国・地域

この著者を引用した国・地域の世界地図アメリカ合衆国: 引用元論文 2,377 件、この内訳の 20.9%中国: 引用元論文 2,078 件、この内訳の 18.3%イタリア: 引用元論文 632 件、この内訳の 5.6%日本: 引用元論文 567 件、この内訳の 5%イギリス: 引用元論文 546 件、この内訳の 4.8%スペイン: 引用元論文 461 件、この内訳の 4.1%フランス: 引用元論文 461 件、この内訳の 4.1%ドイツ: 引用元論文 429 件、この内訳の 3.8%カナダ: 引用元論文 318 件、この内訳の 2.8%韓国: 引用元論文 296 件、この内訳の 2.6%オランダ: 引用元論文 296 件、この内訳の 2.6%オーストラリア: 引用元論文 252 件、この内訳の 2.2%
0%20.9%その他 23.2%

分野

  • Medicine77.8%
  • Biochemistry, Genetics and Molecular Biology15.9%
  • Immunology and Microbiology2.6%
  • Engineering0.5%
  • Neuroscience0.5%
  • Pharmacology, Toxicology and Pharmaceutics0.5%
  • その他2.2%

トピック

  • Lung Cancer Treatments and Mutations12.9%
  • Cancer Immunotherapy and Biomarkers12.4%
  • Lung Cancer Research Studies7.6%
  • Lung Cancer Diagnosis and Treatment7.3%
  • Cancer Genomics and Diagnostics3.1%
  • Immunotherapy and Immune Responses2.4%
  • その他54.3%

共著者

全論文

検索で開く
  1. Durvalumab after Chemoradiotherapy in Stage III Non–Small-Cell Lung Cancer

    著者: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , - New England Journal of Medicine 2017 被引用: 4,539

  2. Overall Survival with Durvalumab after Chemoradiotherapy in Stage III NSCLC

    著者: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Maria Taboada, Phillip A. Dennis, Mustafa Özgüroğlu - New England Journal of Medicine 2018 被引用: 2,800

  3. Updated Overall Survival and PD-L1 Subgroup Analysis of Patients With Extensive-Stage Small-Cell Lung Cancer Treated With Atezolizumab, Carboplatin, and Etoposide (IMpower133)

    著者: , , , , , , , , , , , , , , , , , , , - Journal of Clinical Oncology 2021 被引用: 824

  4. PI3K/Akt signalling pathway and cancer

    著者: , , , , , - Cancer Treatment Reviews 2003 被引用: 2,490

  5. Perioperative Nivolumab and Chemotherapy in Stage III Non–Small-Cell Lung Cancer

    著者: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , - New England Journal of Medicine 2023 被引用: 450

  6. Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial

    著者: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Javier Valdivia, Dolores Isla, Manuel Dómine, Olivier Molinier, Julien Mazières, Nathalie Baize, Rosario García‐Campelo, G. Robinet, Delvys Rodríguez‐Abreu, Guillermo López-Vivanco, Vittorio Gebbia, Lioba Ferrera-Delgado, P. Bombaron, Reyes Bernabé, Alessandra Bearz, Á. Artal, Enrico Cortesi, Christian Rolfo, María Sanchez-Ronco, Ana Drozdowskyj, Cristina Queralt, Itziar de Aguirre, José Luis Ramírez, José Javier Sánchez, Miguel Ángel Molina‐Vila, Miquel Tarón, Luis Paz‐Ares - The Lancet Oncology 2012 被引用: 5,530

  7. Neoadjuvant chemotherapy and nivolumab in resectable non-small-cell lung cancer (NADIM): an open-label, multicentre, single-arm, phase 2 trial

    著者: , , , , , , , , , , , , , , , , , , , , , , , , , , , - The Lancet Oncology 2020 被引用: 828

  8. Five-Year Outcomes From the Randomized, Phase III Trials CheckMate 017 and 057: Nivolumab Versus Docetaxel in Previously Treated Non–Small-Cell Lung Cancer

    著者: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , - Journal of Clinical Oncology 2021 被引用: 661

  9. Overall Survival and Biomarker Analysis of Neoadjuvant Nivolumab Plus Chemotherapy in Operable Stage IIIA Non–Small-Cell Lung Cancer (NADIM phase II trial)

    著者: , , , , , , , , , , , , , , , , , , , , , , , , , , , , - Journal of Clinical Oncology 2022 被引用: 335

  10. Trastuzumab Emtansine (T-DM1) in Patients with Previously Treated HER2-Overexpressing Metastatic Non–Small Cell Lung Cancer: Efficacy, Safety, and Biomarkers

    著者: , , , , , , , , , , , , , , , , - Clinical Cancer Research 2018 被引用: 230

  11. Phase II Trial of Atezolizumab Combined With Carboplatin and Pemetrexed for Patients With Advanced Nonsquamous Non–Small-Cell Lung Cancer With Untreated Brain Metastases (Atezo-Brain, GECP17/05)

    著者: , , , , , , , , , , , , , , , , , - Journal of Clinical Oncology 2023 被引用: 106

  12. Four-year survival with nivolumab in patients with previously treated advanced non-small-cell lung cancer: a pooled analysis

    著者: , , , , , , , , , , , , , , , , , , , - The Lancet Oncology 2019 被引用: 365

  13. A randomised phase II study of osimertinib and bevacizumab versus osimertinib alone as second-line targeted treatment in advanced NSCLC with confirmed EGFR and acquired T790M mutations: the European Thoracic Oncology Platform (ETOP 10-16) BOOSTER trial

    著者: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Solange Peters, Ross A. Soo, Ji‐Youn Han, Martin Früh, Mariano Provencio, Linda Coate, Urania Dafni, Anita Hiltbrunner, Barbara Ruepp, Heidi Roschitzki‐Voser, Anita Hiltbrunner, Adriana Gasca-Ruchti, Nino Giacomelli, Rosita Kammler, Nesa Marti, Lionel Nobs, Mariana Pardo-Contreras, Rita Pfister, Anne‐Christine Piguet, Sabrina Ribeli-Hofmann, Virginia Rodriguez Martinez, Heidi Roschitzki‐Voser, Susanne Roux, Barbara Ruepp, Magdalena Sánchez-Hohl, Mirjam Schneider, Robin Schweri, Sandra Troesch, Isabel Zigomo, Urania Dafni, Zoi Tsourti, Panagiota Zygoura, Marie Kassapian, Katerina Vervita, Georgia Dimopoulou, Charitini Andriakopoulou, Maria Fernandez, Eva Pereira, Carolina Simona, Lisa Tucker, Jillian Burnes, Aisling Barrett, Meghan McGrillen, Catherine Berset, Christine Biaggi, M. Reist, Priska Rentsch, Linda Coate, Sinéad Cuffe, Sayed M.S. Hashemi, Ernest Nadal, Enric Carcereny, Javier de Castro, María Ángeles Sala, Bernabé Reyes, Mariano Provencio Pulla, Rosario García Campelo, Bartomeu Massutí, José López García, Manuel Dómine, Margarita Majem, José Miguel Sánchez, Martin Früh, Christian Britschgi, Miklos Pless, Solange Peters, Ross A. Soo, Chong Ming Yeo, Ji‐Youn Han, Byoung Chul Cho - Annals of Oncology 2021 被引用: 116

  14. Tumor microenvironment gene expression profiles associated to complete pathological response and disease progression in resectable NSCLC patients treated with neoadjuvant chemoimmunotherapy

    著者: , , , , , , , , , , , , , , , , , , , , , , , , - Journal for ImmunoTherapy of Cancer 2022 被引用: 62

  15. Priorities in Cardio-Oncology Basic and Translational Science

    著者: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Tienush Rassaf, Melanie Ricke‐Hoch, Pilar Sepúlveda, Paaladinesh Thavendiranathan, Peter van der Meer, Valentı́n Fuster, Bonnie Ky, Teresa López‐Fernández - JACC CardioOncology 2023 被引用: 43

  16. Perioperative chemotherapy and nivolumab in non-small-cell lung cancer (NADIM): 5-year clinical outcomes from a multicentre, single-arm, phase 2 trial

    著者: , , , , , , , , , , , , , , , , , , , , , , - The Lancet Oncology 2024 被引用: 69

  17. Assessment of the Feasibility and Safety of Durvalumab for Treatment of Solid Tumors in Patients With HIV-1 Infection

    著者: , , , , , , , , , , , , , , , , , , , , , , , , - JAMA Oncology 2020 被引用: 106

  18. Blood biomarkers associated to complete pathological response on NSCLC patients treated with neoadjuvant chemoimmunotherapy included in NADIM clinical trial

    著者: , , , , , , , , , , , , , , , , , , , , , , , , , , , - Clinical and Translational Medicine 2021 被引用: 56

  19. New update to the guidelines on testing predictive biomarkers in non-small-cell lung cancer: a National Consensus of the Spanish Society of Pathology and the Spanish Society of Medical Oncology

    著者: , , , , , , , , , - Clinical & Translational Oncology 2022 被引用: 46

  20. Pretreatment Tissue TCR Repertoire Evenness Is Associated with Complete Pathologic Response in Patients with NSCLC Receiving Neoadjuvant Chemoimmunotherapy

    著者: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , - Clinical Cancer Research 2021 被引用: 67

  21. Evaluation of the clinical use of MGMT methylation in extracellular vesicle-based liquid biopsy as a tool for glioblastoma patient management

    著者: , , , , , , , , , , , , , , , , , , , , - Scientific Reports 2024 被引用: 23

  22. Efficacy and safety of long-acting pasireotide or everolimus alone or in combination in patients with advanced carcinoids of the lung and thymus (LUNA): an open-label, multicentre, randomised, phase 2 trial

    著者: , , , , , , , , , , , , , , , , , , , , , - The Lancet Oncology 2017 被引用: 135

  23. Tumor stem cells fuse with monocytes to form highly invasive tumor-hybrid cells

    著者: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Inmaculada Ibañez de Cáceres, Prudencio Díaz-Agero, María Gutiérrez Fernández, María P. De Miguel, David Sancho, Leon N. Schulte, Rosario Perona, Cristóbal Belda-Iniesta, Lisardo Boscá, Eduardo López‐Collazo - OncoImmunology 2020 被引用: 56

  24. Spatially Preserved Multi-Region Transcriptomic Subtyping and Biomarkers of Chemoimmunotherapy Outcome in Extensive-Stage Small Cell Lung Cancer

    著者: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Javier Baena, Mercedes Herrera, Helena Bote, Magdalena Molero, Vera Adradas, Santiago Ponce-Aix, Ángel Nuñez-Buiza, Álvaro C. Ucero, Susana Hernández, Fernando López‐Ríos, Esther Conde, Luis Paz‐Ares, Jon Zugazagoitia - Clinical Cancer Research 2024 被引用: 13